Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: VRL011
MIFTS: 61

Viral Infectious Disease

Categories: Infectious diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Viral Infectious Disease

About this section

MalaCards integrated aliases for Viral Infectious Disease:

Name: Viral Infectious Disease 12 15
Arbovirus Infections 43 17 71
Virus Infection 12 54
Virus Diseases 43 71
Viral Disease 12 17
Viral Infections 42
Virus Infections 15
Viral Infection 12

Classifications:

MalaCards categories:
Global: Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:934
ICD9CM 34 060-066.99
NCIt 49 C3439 C34396
SNOMED-CT 67 34014006 40610006
UMLS 71 C0003723 C0042769
Sources

Summaries for Viral Infectious Disease

About this section
MedlinePlus : 42 Viruses are very tiny germs. They are made of genetic material inside of a protein coating. Viruses cause familiar infectious diseases such as the common cold, flu and warts. They also cause severe illnesses such as HIV/AIDS, smallpox, and Ebola. Viruses are like hijackers. They invade living, normal cells and use those cells to multiply and produce other viruses like themselves. This can kill, damage, or change the cells and make you sick. Different viruses attack certain cells in your body such as your liver, respiratory system, or blood. When you get a virus, you may not always get sick from it. Your immune system may be able to fight it off. For most viral infections, treatments can only help with symptoms while you wait for your immune system to fight off the virus. Antibiotics do not work for viral infections. There are antiviral medicines to treat some viral infections. Vaccines can help prevent you from getting many viral diseases.

MalaCards based summary : Viral Infectious Disease, also known as arbovirus infections, is related to chronic active epstein-barr virus infection and bell's palsy, and has symptoms including fever, pruritus and pathological conditions, signs and symptoms. An important gene associated with Viral Infectious Disease is IFNA1 (Interferon Alpha 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Ephedrine and Pseudoephedrine have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and testes, and related phenotypes are Strongly decreased CFP-tsO45G cell surface transport and Strongly decreased CFP-tsO45G cell surface transport

Disease Ontology : 12 A disease by infectious agent that results in infection, has material basis in Viruses.

Wikipedia : 74 A viral disease (or viral infection, or infectious disease) occurs when an organism's body is invaded by... more...

Sources

Related Diseases for Viral Infectious Disease

About this section

Diseases related to Viral Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2444)
# Related Disease Score Top Affiliating Genes
1 chronic active epstein-barr virus infection 35.2 IL2 IL10 IFNG
2 bell's palsy 33.7 MX1 IFNA1 CD40LG CD4
3 acute disseminated encephalomyelitis 33.6 IL10 IFNB1 CD40LG
4 rabies 33.6 TLR3 MX1 IRF7 IRF3 IFNA1 DDX58
5 hand, foot and mouth disease 33.6 TLR7 TLR3 IL10 IFNG DDX58
6 intermediate uveitis 33.6 TNF IL2 IL10 IFNG CCR5
7 poliomyelitis 33.5 TNF IL10 IFNG CD40LG CD4
8 hepatitis a 33.5 TNF TLR3 MAVS IL10 IFNG IFNA2
9 mumps 33.5 TNF TLR3 MX1 IL2 IL10 IFNG
10 chikungunya 33.5 TNF TLR7 MAVS DDX58
11 chickenpox 33.5 TNF TLR3 IL2 IL10 IFNG IFNB1
12 rubella 33.5 TNF TLR3 IL2 IL10 IFNG IFNB1
13 measles 33.5 TNF TLR7 TLR3 IRF7 IRF3 IL2
14 biliary atresia 33.3 TNF TLR3 MX1 IFNG GPT
15 lymphocytic choriomeningitis 33.3 MAVS IRF3 DDX58
16 tick-borne encephalitis 33.3 TLR3 IL10 IFNB1 IFNA1 DDX58 CCR5
17 tonsillitis 33.3 TNF TLR3 IL2 IL10 IFNG
18 hemorrhagic cystitis 33.3 TNF IL2 CD4
19 cryptogenic organizing pneumonia 33.3 TNF CD40LG CD4
20 hyper ige syndrome 33.3 TNF TLR3 IL10 IFNG
21 aphthous stomatitis 33.3 TNF IL2 IL10 IFNG
22 staphylococcal toxic shock syndrome 33.2 TNF IFNG
23 optic neuritis 33.2 TNF IL10 CCR5
24 newcastle disease 33.1 TNF TLR3 IRF7 IRF3 IFNB1 IFNA1
25 lassa fever 33.1 IRF3 IFNA1 IFIH1 DDX58 CD40LG CD4
26 ebola hemorrhagic fever 33.1 IFNB1 IFNA1 CD40LG CD4
27 anogenital venereal wart 33.1 TLR7 TLR3 IL2 IFNB1 IFNA1 CD4
28 venezuelan equine encephalitis 33.1 IRF7 IFNG IFNB1 IFNA1
29 japanese encephalitis 33.1 TNF TLR7 TLR3 IFNB1 IFNA1
30 crimean-congo hemorrhagic fever 33.1 TNF TLR7 TLR3 MX1 IFNB1 IFNA1
31 hepatitis e 33.1 TNF TLR3 IFNG IFNB1 GPT DDX58
32 west nile encephalitis 33.1 TLR7 CD40LG CD4 CCR5
33 hantavirus hemorrhagic fever with renal syndrome 33.1 TNF MX1 DDX58 CD40LG CD4
34 herpes simplex 33.1 TNF TLR3 IRF7 IRF3 IFNB1 IFNA1
35 coronavirus infectious disease 33.1 TNF TLR3 IRF3 IFNB1 IFNA1 IFIH1
36 hepatitis d 33.1 IFNA2 IFNA1 GPT CD40LG
37 common wart 33.1 TLR7 IFNA1 CD4
38 progressive multifocal leukoencephalopathy 33.1 TNF IL2 IFNB1 CD40LG CD4
39 dengue disease 33.1 TNF IFNB1 IFNA1 CD40LG
40 hepatitis b 33.1 TNF TLR3 MX1 IFNG IFNB1 IFNA2
41 vaccinia 33.1 TNF MAVS IRF7 IRF3 IL2 IFNB1
42 common cold 33.1 TNF TLR3 IL10 IFNA2 CD4
43 monkeypox 33.1 IFNA1 CD40LG CD4
44 west nile fever 33.1 CD40LG CD4 CCR5
45 subacute sclerosing panencephalitis 33.1 TNF TLR3 MX1 IL2 IL10 IFNG
46 hantavirus pulmonary syndrome 33.1 IRF3 IFNB1 CD40LG
47 nasopharyngitis 33.0 TNF IFNB1 GPT
48 aicardi-goutieres syndrome 33.0 TLR7 TLR3 MX1 MAVS IRF7 IRF3
49 smallpox 33.0 TNF ITIH4 IL2 IFNG
50 influenza 33.0 TNF TLR7 TLR3 MX1 MAVS IRF7

Graphical network of the top 20 diseases related to Viral Infectious Disease:



Diseases related to Viral Infectious Disease
Sources

Symptoms & Phenotypes for Viral Infectious Disease

About this section

UMLS symptoms related to Viral Infectious Disease:


fever, pruritus, pathological conditions, signs and symptoms

GenomeRNAi Phenotypes related to Viral Infectious Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Strongly decreased CFP-tsO45G cell surface transport GR00360-A-1 9.4 CCR5 GPT IFIH1 MAVS TLR3 TLR7
2 Strongly decreased CFP-tsO45G cell surface transport GR00360-A-2 9.4 CCR5 GPT IFIH1 MAVS TLR3 TLR7

MGI Mouse Phenotypes related to Viral Infectious Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.2 CCR5 CD4 CD40LG DDX58 IFIH1 IFNB1
2 cellular MP:0005384 10.18 CCR5 CD4 CD40LG DDX58 IFIH1 IFNG
3 homeostasis/metabolism MP:0005376 10.13 CCR5 CD4 CD40LG DDX58 IFIH1 IFNB1
4 immune system MP:0005387 10.03 CCR5 CD4 CD40LG DDX58 IFIH1 IFNB1
5 digestive/alimentary MP:0005381 9.97 CCR5 CD4 DDX58 IFNG IL10 IL2
6 liver/biliary system MP:0005370 9.56 CCR5 DDX58 IFIH1 IFNG IL10 IL2
7 neoplasm MP:0002006 9.28 CCR5 DDX58 IFNB1 IFNG IL10 IL2
Sources

Drugs & Therapeutics for Viral Infectious Disease

About this section

Drugs for Viral Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 654)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ephedrine Approved Phase 4 299-42-3 9294
2
Pseudoephedrine Approved Phase 4 90-82-4 7028
3
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
4
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
5
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
6
Bevacizumab Approved, Investigational Phase 4 216974-75-3
7
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
8
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
9
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
10
Cytarabine Approved, Experimental, Investigational Phase 4 147-94-4, 65-46-3 6253
11
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
12
Pancrelipase Approved, Investigational Phase 4 53608-75-6
13
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
14
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
15
Racepinephrine Approved Phase 4 329-65-7 838
16
Montelukast Approved Phase 4 158966-92-8 5281040
17
Acetaminophen Approved Phase 4 103-90-2 1983
18
Adefovir dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
19
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
20
Didanosine Approved Phase 4 69655-05-6 50599
21
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
22
Thyme Approved Phase 4
23
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
24
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
25
Simvastatin Approved Phase 4 79902-63-9 54454
26
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
27
Ceftriaxone Approved Phase 4 73384-59-5 5361919 5479530
28
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
29
Polyestradiol phosphate Approved Phase 4 28014-46-2
30
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
31
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
32
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
33
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
34
Petrolatum Approved, Investigational Phase 4 8009-03-8
35
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
36
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
37
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
38
Foscarnet Approved Phase 4 4428-95-9, 63585-09-1 3415
39
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
40
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
41
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
42
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
43
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
44
Menthol Approved Phase 4 2216-51-5 16666
45
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
46
Clarithromycin Approved Phase 4 81103-11-9 84029
47
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
48
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
49
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
50
Dolutegravir Approved Phase 4 1051375-16-6 54726191

Interventional clinical trials:

(show top 50) (show all 2332)
# Name Status NCT ID Phase Drugs
1 Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial. Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
2 Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial Unknown status NCT00663182 Phase 4 Entecavir
3 A Double Blind Randomised Placebo Controlled Trial of Montelukast in the Treatment of Acute Persistent Cough in Young People and Adults in Primary Care Unknown status NCT01279668 Phase 4 Montelukast;Placebo
4 A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
5 Polyomavirus BK Nephropathy After Renal Transplantation: Randomized Clinical Trial to Demonstrate That Switching to mTOR Inhibitor is More Effective Than a Reduction of Immunosuppressive Therapy Unknown status NCT01289301 Phase 4 mTOR inhibitor (everolimus);cyclosporine or tacrolimus
6 Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children Unknown status NCT00494624 Phase 4 prednisolone
7 A Multicenter, Open-label, Prospective Study to Evaluate Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4 Entecavir + Tenofovir (MDR group)
8 Phase IV Study of the Efficacy of Entecavir in Patients With Chronic Hepatitis B Virus Infection and Persistently Normal Alanine Aminotransferase Unknown status NCT01833611 Phase 4 Entecavir;placebo
9 Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine Unknown status NCT00564057 Phase 4 candesartan;lercanidipine
10 A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection Unknown status NCT00939068 Phase 4 Telbivudine
11 Antiviral and Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) Virus Pneumonia: Multi-centre, Prospective, Randomized Controlled Study Unknown status NCT00936013 Phase 4 oseltamivir;oseltamivir and chinese medicinal herbs
12 Double-blind, Randomized, Placebo-controlled Clinical Study Investigating Efficacy and Safety of Arbidol (Umifenovir) in Treatment and Prophylaxis of Influenza and Common Cold. Unknown status NCT01651663 Phase 4 Arbidol (Umifenovir);Arbidol (Umifenovir)
13 A Phase IV, Multisite Study of the Treatment of Chronic Hepatitis C Virus Infection Genotype 1 in a Real World Large Health Maintenance Organization: An Evaluation of Real World Sustained Virological Response and Patient Reported Outcomes Unknown status NCT02461745 Phase 4 ombitasvir, paritaprevir/r, dasabuvir + ribavirin;ombitasvir, paritaprevir/r, dasabuvir
14 A Prospective, Open-label, Multicenter Study of Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
15 Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
16 Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial Unknown status NCT01649245 Phase 4 Reiferon retard
17 An Open-label, Multi-center, Randomized Study Comparing the Effects of Oral Hypoglycemic Agents on Viral Kinetics of Chronic Hepatitis C Patients Receiving Pegylated Interferon Alfa 2b Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
18 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled，Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
19 Fractional Concentration of Exhaled NO(FeNO) to Direct The Treatment of Sub-acute Cough：A Prospective, Open Label, Randomized and Placebo-Controlled Trial Unknown status NCT02655562 Phase 4 Montelukast
20 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
21 The Effectiveness and Feasibility of Using Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus-drug Test and Follow-up Study Unknown status NCT01312012 Phase 4 antiviral therapy
22 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Unknown status NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
23 Management of Active and Established Corneal Neovascularisation to Prevent Visual Impairment Unknown status NCT02594423 Phase 4 Bevacizumab
24 Direct Observed Therapy With Ledipasvir/Sofosbuvir in Treatment-naïve Patients With Chronic Genotype 1 HCV (Hepatitis C Virus) Infection Receiving Opiate Substitution Therapy Unknown status NCT02638233 Phase 4 Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
25 Bronchiolitis All-study, SE-Norway What is the Optimal Inhalation Treatment for Children 0-12 Months With Acute Bronchiolitis? Unknown status NCT00817466 Phase 4 Racemic adrenaline;Isotonic saline
26 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
27 1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection Unknown status NCT00885625 Phase 4
28 Randomised Double Blind Placebo Controlled Multicenter Study for Evaluation of Clinical Efficacy and Safety of Ingavirin 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults. Completed NCT03154515 Phase 4 Ingavirin;Placebo
29 Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis Completed NCT01883180 Phase 4 ATG
30 Multicentre Double-blind Placebo-controlled Parallel Group Randomized Clinical Trial of Efficacy and Safety of Anaferon in the Treatment of Acute Respiratory Viral Completed NCT03707912 Phase 4 Anaferon;Placebo
31 Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy Completed NCT01819792 Phase 4
32 Palatability Testing of a New Paediatric Formulation of Valacyclovir for the Prophylaxis and Treatment of VZV and HSV Infections in Children Completed NCT01682109 Phase 4 Valacyclovir
33 Treatment of Recently Acquired Hepatitis C Virus Infection Completed NCT01336010 Phase 4 Peginterferon alfa-2a;Ribavirin
34 Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection Completed NCT01097395 Phase 4 ribavirin
35 Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study Completed NCT01353339 Phase 4 Levofloxacin
36 International Multicenter Double-blind Placebo-controlled Randomized Parallel Group Clinical Trial of Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children Completed NCT02072174 Phase 4 Anaferon for Children
37 Randomized Study on the Efficacy and Safety of Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation Completed NCT00383864 Phase 4 Pegylated interferon and ribavirin
38 International Multicenter Double-blind Placebo-Controlled Parallel-Group Randomized Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in Children Completed NCT03039621 Phase 4 Ergoferon;Placebo
39 Pilot Study to Assess the Effect of Prophylactic Antipyretics on Immune Responses and Rates of Fever After 2013-2014 Inactivated Influenza Vaccine (IIV) in Young Children Completed NCT01946594 Phase 4
40 Treatment of Acute Hepatitis C Virus Infection in Injection Drug Users With Pegylated Interferon for 24 Weeks Completed NCT00194480 Phase 4 Pegylated Interferon
41 A Randomized Controlled Trial on the Effect of Fever Suppression by Antipyretics on Influenza Completed NCT01891084 Phase 4 Paracetamol;Placebo;Backup NSAID ibuprofen
42 Safety and Efficacy of Mycophenolic Acid Withdrawal With Conversion to Zortress (Everolimus) in Renal Transplant Recipients With BK Virus Infection Completed NCT01624948 Phase 4 Everolimus;Mycophenolic acid dose reduction
43 Open, Randomised Study Comparing Preemptive Therapy With Intravenous Ganciclovir With and Without Additional Oral Ganciclovir for CMV Prophylaxis in Immunosuppressed Renal Transplant Patients Receiving Monitoring of CMV Viral Load Completed NCT00373165 Phase 4 Ganciclovir
44 Prevention of RSV Infections in Bone Marrow Transplant Recipients Completed NCT00001903 Phase 4 RSV Polyclonal Immunoglobulin
45 Induction of HBsAg Decline Using an add-on Treatment of Peginterferon Alfa-2a in HBeAg-negative Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogous (PAS) Completed NCT01373684 Phase 4 Peginterferon alfa-2a;Nucleos(t)ide analogue
46 Safety and Immunogenicity of Fluzone® Influenza Virus Vaccine (2006-2007 Formulation) Among Healthy Children Immunized in Fall 2005 With Fluzone Vaccine or Placebo Completed NCT00390884 Phase 4
47 Direct and Indirect Benefits of Influenza Vaccination in Schools and Households Completed NCT00981513 Phase 4
48 Generic Velpatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Completed NCT03250910 Phase 4 Sofosbuvir and Velpatasvir;Ribavirin
49 A Multicenter Study Evaluating the Efficacy and Safety of 12 Weeks Versus 24 Weeks Peginterferon Alfa-2a 40KD Combination Therapy With Ribavirin in Interferon Naïve Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Completed NCT00143000 Phase 4 Peginterferon alfa-2a 40KD and Ribavirin
50 Randomized Placebo-controlled Trial of Montelukast in Modulating Exacerbations of Asthma in Children, September 2005 Completed NCT00196547 Phase 4 Montelukast (drug)

Search NIH Clinical Center for Viral Infectious Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


BISMUTH HYDROXIDE
BISMUTH RESORCIN COMPOUND
bismuth subcarbonate
BISMUTH SUBCARBONATE PWDR
bismuth subcitrate
bismuth subgallate
BISMUTH SUBIODIDE
bismuth subnitrate
BISMUTH SUBNITRATE PWDR
bismuth subsalicylate
BISMUTH-FORMIC-IODIDE
Idoxuridine
Nucleoside Analog Antiviral [EPC]
Ribavirin
Trifluridine

Cochrane evidence based reviews: arbovirus infections

Sources

Genetic Tests for Viral Infectious Disease

About this section
Sources

Anatomical Context for Viral Infectious Disease

About this section

MalaCards organs/tissues related to Viral Infectious Disease:

40
Liver, T Cells, Testes, Kidney, Lung, Skin, Bone
Sources

Publications for Viral Infectious Disease

About this section

Articles related to Viral Infectious Disease:

(show top 50) (show all 2315)
# Title Authors PMID Year
1
Redox-Modulating Agents in the Treatment of Viral Infections. 42
32521619 2020
2
Massively multiplexed nucleic acid detection with Cas13. 42
32349121 2020
3
Contributions of maternal and fetal antiviral immunity in congenital disease. 42
32381717 2020
4
Arboviruses and Blood Meal Sources in Zoophilic Mosquitoes at Human-Wildlife Interfaces in Kenya. 61
32155389 2020
5
Prevalence of locally undetected acute infections of Flaviviruses in North-Eastern Nigeria. 61
32561377 2020
6
Antiviral Natural Products for Arbovirus Infections. 61
32560438 2020
7
Experience in diagnosing congenital Zika syndrome in Brazilian children born to asymptomatic mothers. 61
32165128 2020
8
A Review: Wolbachia-Based Population Replacement for Mosquito Control Shares Common Points with Genetically Modified Control Approaches. 61
32456036 2020
9
Vector competence of Malaysian Aedes aegypti to Zika virus and impact of sequential arbovirus infections. 61
32389451 2020
10
The Endless Challenges of Arboviral Diseases in Brazil. 61
32397512 2020
11
Reliable Serological Diagnostic Tests for Arboviruses: Feasible or Utopia? 61
31864844 2020
12
Imported Arbovirus Infections in Spain, 2009-2018. 61
32186486 2020
13
Vector-borne diseases in waste pickers in Brasilia, Brazil. 61
32087540 2020
14
Expansion of the Distribution of Aedes albopictus (Diptera: Culicidae): New Records in Northern Argentina and Their Implications From an Epidemiological Perspective. 61
32020186 2020
15
Ophthalmic manifestations of arbovirus infections in adults. 61
31679764 2020
16
Seroprevalence of yellow fever, dengue, West Nile and chikungunya viruses in children in Teso South Sub-County, Western Kenya. 61
31712089 2020
17
Seroepidemiology of dengue and chikungunya fever in patients with rash and fever in Iran, 2017. 61
32100659 2020
18
The rise or fall of neglected tropical diseases in East Asia Pacific. 61
31550453 2020
19
Review of Phytochemical Compounds as Antiviral Agents against Arboviruses from the Genera Flavivirus and Alphavirus. 61
31969106 2020
20
Pan-viral protection against arboviruses by activating skin macrophages at the inoculation site. 61
31969486 2020
21
Importance of microenvironment to arbovirus vector distribution in an urban area, São Paulo, Brazil. 61
32267458 2020
22
Immunohistochemical identification of antigens of canine distemper virus in neotropical felids from Southern Brazil. 61
31916410 2020
23
New premises for sanitation in arbovirus infections control in Brazil. 61
32402002 2020
24
Enhancing Preparedness for Arbovirus Infections with a One Health Approach: The Development and Implementation of Multisectoral Risk Assessment Exercises. 61
32382554 2020
25
Yellow Fever Virus Reemergence and Spread in Southeast Brazil, 2016-2019. 61
31597773 2019
26
Improving immunological insights into the ferret model of human viral infectious disease. 61
31583825 2019
27
Identification of B-Cell Epitopes with Potential to Serologicaly Discrimnate Dengue from Zika Infections. 61
31752352 2019
28
Endemic Disease Control Agents' perception on the fight against Aedes aegypti and the prevention of arbovirus infections in Brazil. 61
31584945 2019
29
The phylogenetic approach for viral infectious disease evolution and epidemiology: An updating review. 61
31243773 2019
30
Efficacy of the combination of superficial shaving with photodynamic therapy for recalcitrant periungual warts. 61
31252143 2019
31
Osteoarticular manifestations of Mayaro virus infection. 61
31361271 2019
32
Environmental suitability for Aedes aegypti and Aedes albopictus and the spatial distribution of major arboviral infections in Mexico. 61
31528740 2019
33
Epidemiological Characteristics and Spatial Analysis of Tick-Borne Encephalitis in Jilin Province, China. 61
31074410 2019
34
Diagnostic Performance of Dengue Virus Envelope Domain III in Acute Dengue Infection. 61
31311082 2019
35
Atovaquone Inhibits Arbovirus Replication through the Depletion of Intracellular Nucleotides. 61
30894466 2019
36
Detection of chikungunya virus-specific IgM on laser-cut paper-based device using pseudo-particles as capture antigen. 61
30734316 2019
37
Mycoplasma bovis and viral agents associated with the development of bovine respiratory disease in adult dairy cows. 61
31232526 2019
38
Exome-wide search and functional annotation of genes associated in patients with severe tick-borne encephalitis in a Russian population. 61
31122248 2019
39
Understanding social inequalities in Zika infection and its consequences: A model of pathways and policy entry-points. 61
30301438 2019
40
Implementation of the One Health approach to fight arbovirus infections in the Mediterranean and Black Sea Region: Assessing integrated surveillance in Serbia, Tunisia and Georgia. 61
30724030 2019
41
Prevalence of avian influenza, Newcastle disease, and infectious bronchitis viruses in broiler flocks infected with multifactorial respiratory diseases in Iran, 2015-2016. 61
30377950 2019
42
Metabolomic Insights into Human Arboviral Infections: Dengue, Chikungunya, and Zika Viruses. 61
30845653 2019
43
Emerging and Reemerging Aedes-Transmitted Arbovirus Infections in the Region of the Americas: Implications for Health Policy. 61
30676796 2019
44
Spatiotemporal characteristics and primary influencing factors of typical dengue fever epidemics in China. 61
30922405 2019
45
Fulminant myocarditis associated with severe fever with thrombocytopenia syndrome: a case report. 61
30885147 2019
46
The proportion, origin and pro-inflammation roles of low density neutrophils in SFTS disease. 61
30717709 2019
47
Diagnostic Value of Platelet and Leukocyte Counts in the Differential Diagnosis of Fever in the Returning Traveler. 61
30526735 2019
48
Differential Shedding and Antibody Kinetics of Zika and Chikungunya Viruses, Brazil. 61
30666934 2019
49
Development of an anti-hepatitis B virus (HBV) agent through the structure-activity relationship of the interferon-like small compound CDM-3008. 61
30552008 2019
50
Evaluation of the impact of live pig trade network, vaccination coverage and socio-economic factors in the classical swine fever eradication program in Peru. 61
30621896 2019